Fitzharris M, Cripps RA, Lee BB. Estimating the global incidence of traumatic spinal cord injury. Spinal Cord. 2014;52:117–22.

Article  CAS  PubMed  Google Scholar 

New PW, Cripps RA, Bonne LB. Global maps of non-traumatic spinal cord injury epidemiology: towards a living data repository. Spinal Cord. 2014;52:97–109.

Article  CAS  PubMed  Google Scholar 

Hamid R, Averbeck MA, Chiang H, Garcia A, Al Mousa RT, Oh SJ, et al. Epidemiology and pathophysiology of neurogenic bladder after spinal cord injury. World J Urol. 2018;36:1517–27.

Article  PubMed  Google Scholar 

Wallin MT, Culpepper WJ, Nichols E, Bhutta ZA, Gebrehiwot TT, Hay SI, et al. Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:269–85.

Article  Google Scholar 

Phé V, Chartier-Kastler E, Panicker JN. Management of neurogenic bladder in patients with multiple sclerosis. Nat Rev Urol. 2016;13:275–88.

Article  PubMed  Google Scholar 

Przydacz M, Denys P, Corcos J. What do we know about neurogenic bladder prevalence and management in developing countries and emerging regions of the world? Ann Phys Rehabil Med. 2017;60:341–6.

Article  PubMed  Google Scholar 

Zhang ZX, Roman GC, Hong Z, Wu CB, Qu QM, Huang JB, et al. Parkinson’s disease in China: prevalence in Beijing, Xian, and Shanghai. Lancet. 2005;365:595–7.

Article  PubMed  Google Scholar 

Palma-Zamora ID, Atiemo HO. Understanding the economic impact of neurogenic lower urinary tract dysfunction. Urol Clin North Am. 2017;44:333–43.

Article  PubMed  Google Scholar 

Jaggi A, Nazir J, Fatoye F, Siddiqui E, Choudhury N, Argoubi R, et al. Drug utilization patterns and healthcare resource use and costs in patients with neurogenic bladder in the United Kingdom: a retrospective primary care database study. Neurourol Urodyn. 2019;38:1278–89.

Article  PubMed  PubMed Central  Google Scholar 

Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making. 2013;33:641–56.

Article  PubMed  PubMed Central  Google Scholar 

McClurg D, Elders A, Hagen S, Mason H, Booth J, Cunnington A-L, et al. Stimulation of the tibial nerve—a randomised trial for urinary problems associated with Parkinson’s—the STARTUP trial. Age Ageing. 2022. https://doi.org/10.1093/ageing/afac114.

Article  PubMed  PubMed Central  Google Scholar 

Marzouk MH, Darwish MH, El-Tamawy MS, Morsy S, Abbas RL, Ali AS. Posterior tibial nerve stimulation as a neuromodulation therapy in treatment of neurogenic overactive bladder in multiple sclerosis: a prospective randomized controlled study. Mult Scler Relat Disord. 2022;68: 104252.

Article  PubMed  Google Scholar 

Kennelly M, Cruz F, Herschorn S, Abrams P, Onem K, Solomonov VK, et al. Efficacy and safety of abobotulinumtoxina in patients with neurogenic detrusor overactivity incontinence performing regular clean intermittent catheterization: pooled results from two phase 3 randomized studies (CONTENT1 and CONTENT2). Eur Urol. 2022;82:223–32.

Article  CAS  PubMed  Google Scholar 

Giannantoni A, Gubbiotti M, Rubilotta E, Balzarro M, Antonelli A, Bini V. IncobotulinumtoxinA versus onabotulinumtoxinA intradetrusor injections in patients with neurogenic detrusor overactivity incontinence: a double-blind, randomized, non-inferiority trial. Minerva Urol Nephrol. 2022;74:625–35.

Article  PubMed  Google Scholar 

Moussa M, Chakra MA, Dabboucy B, Fares Y, Dellis A, Papatsoris A. The safety and effectiveness of mirabegron in Parkinson’s disease patients with overactive bladder: a randomized controlled trial. Scand J Urol. 2021;56:66–72.

Article  PubMed  Google Scholar 

Honda M, Yokoyama O, Takahashi R, Matsuda T, Nakayama T, Mogi T. Botulinum toxin injections for Japanese patients with urinary incontinence caused by neurogenic detrusor overactivity: clinical evaluation of onabotulinumtoxinA in a randomized, placebo-controlled, double-blind trial with an open-label extension. Int J Urol. 2021;28:906–12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cho SY, Jeong SJ, Lee S, Kim J, Lee SH, Choo MS, et al. Mirabegron for treatment of overactive bladder symptoms in patients with Parkinson’s disease: a double-blind, randomized placebo-controlled trial (Parkinson’s Disease Overactive bladder Mirabegron, PaDoMi Study). Neurourol Urodyn. 2021;40:286–94.

Article  PubMed  Google Scholar 

Chen H, Xie K, Jiang C. A single-blind randomized control trial of trigonal versus nontrigonal Botulinum toxin-A injections for patients with urinary incontinence and poor bladder compliance secondary to spinal cord injury. J Spinal Cord Med. 2021;44:757–64.

Article  CAS  PubMed  Google Scholar 

Welk B, McKibbon M. A randomized, controlled trial of transcutaneous tibial nerve stimulation to treat overactive bladder and neurogenic bladder patients. Can Urol Assoc J [Internet]. 2020;14. Available from: https://www-embase-com-443.webvpn.cams.cn/search/results?subaction=viewrecord&id=L2005837572&from=export.

Tornic J, Liechti MD, Stalder SA, Birkhäuser V, van der Lely S, Leitner L, et al. Transcutaneous tibial nerve stimulation for treating neurogenic lower urinary tract dysfunction: a pilot study for an international multicenter randomized controlled trial. Eur Urol Focus. 2020;6:909–15.

Article  PubMed  Google Scholar 

McDonald C, Rees J, Winge K, Newton JL, Burn DJ. Bladder training for urinary tract symptoms in Parkinson disease. Neurology. 2020. https://doi.org/10.1212/wnl.0000000000008931.

Article  PubMed  PubMed Central  Google Scholar 

Chen H, Wang C, Zhou M, Yan Chan P, Lo Yam L, Lok Lam W, et al. Electroacupuncture for post-stroke overactive bladder: a multi-centre pilot randomized controlled trial. Acupunct Med. 2020;39:175–83.

Article  PubMed  Google Scholar 

Araujo TG, Schmidt AP, Sanches PRS, Silva Junior DP, Rieder CRM, Ramos JGL. Transcutaneous tibial nerve home stimulation for overactive bladder in women with Parkinson’s disease: a randomized clinical trial. Neurourol Urodyn. 2020;40:538–48.

Article  PubMed  Google Scholar 

Yonguc T, Sefik E, Inci I, Kusbeci OY, Celik S, Aydın ME, et al. Randomized, controlled trial of fesoterodine fumarate for overactive bladder in Parkinson’s disease. World J Urol. 2019;38:2013–9.

Article  PubMed  Google Scholar 

Vaughan CP, Burgio Kathryn L, Goode PS, Juncos JL, McGwin G, Muirhead L, et al. Behavioral therapy for urinary symptoms in Parkinson’s disease: a randomized clinical trial. Neurourol Urodyn. 2019;38:1737–44.

Article  PubMed  PubMed Central  Google Scholar 

Stampas A, Korupolu R, Zhu L, Smith CP, Gustafson K. Safety, feasibility, and efficacy of transcutaneous tibial nerve stimulation in acute spinal cord injury neurogenic bladder: a randomized control pilot trial. Neuromodulation. 2019;22:716–22.

Article  PubMed  Google Scholar 

Welk B, Hickling D, McKibbon M, Radomski S, Ethans K. A pilot randomized-controlled trial of the urodynamic efficacy of mirabegron for patients with neurogenic lower urinary tract dysfunction. Neurourol Urodyn. 2018;12:2810–7.

Article  Google Scholar 

Tullman M, Chartier-Kastler E, Kohan A, Keppenne V, Brucker BM, Egerdie B, et al. Low-dose onabotulinumtoxinA improves urinary symptoms in noncatheterizing patients with MS. Neurology. 2018;91:e657–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Krhut J, Borovička V, Bílková K, Sýkora R, Míka D, Mokriš J, et al. Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-prospective, randomized, double-blind, placebo-controlled study. Neurourol Urodyn. 2018;37:2226–33.

Article  CAS  PubMed  Google Scholar 

Guo G, Kang Y. Effectiveness of neuromuscular electrical stimulation therapy in patients with urinary incontinence after stroke. Medicine. 2018;97: e13702.

Article  PubMed  PubMed Central  Google Scholar 

Ferreira RS, D’Ancona CAL, Oelke M, Carneiro MR. Intradetrusor onabotulinumtoxinA injections are significantly more efficacious than oral oxybutynin for treatment of neurogenic detrusor overactivity: results of a randomized, controlled, 24-week trial. Einstein (Sao Paulo, Brazil). 2018;16:eAO4207.

PubMed  PubMed Central  Google Scholar 

Denys P, Del Popolo G, Amarenco G, Karsenty G, Le Berre P, Padrazzi B, et al. Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units dysport® (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): a randomised placebo-controlled phase IIa study. Neurourol Urodyn. 2017;36:457–62.

Article  CAS  PubMed